ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS)

19.26
-0.01
(-0.05%)
19.01
-0.25
( -1.30% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
19.01
Bid
19.01
Ask
19.65
Volume
1,625
0.00 Day's Range 0.00
16.10 52 Week Range 43.61
Market Cap
Previous Close
19.26
Open
-
Last Trade
13
@
19.01
Last Trade Time
09:29:15
Financial Volume
-
VWAP
-
Average Volume (3m)
2,739,306
Shares Outstanding
125,682,260
Dividend Yield
-
PE Ratio
-12.23
Earnings Per Share (EPS)
-1.57
Revenue
781.37M
Net Profit
-197.88M

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the... Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
-
Apellis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APLS. The last closing price for Apellis Pharmaceuticals was $19.26. Over the last year, Apellis Pharmaceuticals shares have traded in a share price range of $ 16.10 to $ 43.61.

Apellis Pharmaceuticals currently has 125,682,260 shares outstanding. The market capitalization of Apellis Pharmaceuticals is $2.42 billion. Apellis Pharmaceuticals has a price to earnings ratio (PE ratio) of -12.23.

APLS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.32-1.6554578375619.3319.9618.75193046119.34947538CS
42.6616.269113149816.3519.9616.34247825518.22121276CS
12-5-20.824656393224.0124.87516.1273930619.17844478CS
26-13.59-41.687116564432.635.70516.1229234323.50313134CS
52-23.65-55.438349742142.6643.6116.1234415727.90579736CS
156-20.65-52.067574382239.6694.7516.1214645743.77154602CS
260-11.2-37.07381661730.2194.7516.1166510743.80632883CS

APLS - Frequently Asked Questions (FAQ)

What is the current Apellis Pharmaceuticals share price?
The current share price of Apellis Pharmaceuticals is $ 19.01
How many Apellis Pharmaceuticals shares are in issue?
Apellis Pharmaceuticals has 125,682,260 shares in issue
What is the market cap of Apellis Pharmaceuticals?
The market capitalisation of Apellis Pharmaceuticals is USD 2.42B
What is the 1 year trading range for Apellis Pharmaceuticals share price?
Apellis Pharmaceuticals has traded in the range of $ 16.10 to $ 43.61 during the past year
What is the PE ratio of Apellis Pharmaceuticals?
The price to earnings ratio of Apellis Pharmaceuticals is -12.23
What is the cash to sales ratio of Apellis Pharmaceuticals?
The cash to sales ratio of Apellis Pharmaceuticals is 3.1
What is the reporting currency for Apellis Pharmaceuticals?
Apellis Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Apellis Pharmaceuticals?
The latest annual turnover of Apellis Pharmaceuticals is USD 781.37M
What is the latest annual profit for Apellis Pharmaceuticals?
The latest annual profit of Apellis Pharmaceuticals is USD -197.88M
What is the registered address of Apellis Pharmaceuticals?
The registered address for Apellis Pharmaceuticals is 108 LAKELAND AVE, KENT, DOVER, DELAWARE, 19901
What is the Apellis Pharmaceuticals website address?
The website address for Apellis Pharmaceuticals is www.apellis.com
Which industry sector does Apellis Pharmaceuticals operate in?
Apellis Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
1,000
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
1,000
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
CGBSCrown LNG Holdings Ltd
$ 0.084
(0.00%)
336.17M
HCTIHealthcare Triangle Inc
$ 0.03
(0.00%)
192.53M
GNLNGreenlane Holdings Inc
$ 0.0154
(0.00%)
159.38M
USEGUS Energy Corp
$ 1.42
(0.00%)
52.04M
ICONIcon Energy Corporation
$ 1.79
(0.00%)
33.11M

APLS Discussion

View Posts
Dennisb68 Dennisb68 8 months ago
IKT is having a great run!
👍️0
Monksdream Monksdream 9 months ago
APLS at a bottom channel
👍️0
Dennisb68 Dennisb68 2 years ago
$60.00, that didn’t take long!
👍️0
Dennisb68 Dennisb68 2 years ago
I like the way this traded today, $60 in the near future on news?
👍️0
Dennisb68 Dennisb68 2 years ago
Holding up well..
👍️0
doholic11 doholic11 2 years ago
Finally! Back up 14% today.
👍️0
pitacorp pitacorp 2 years ago
Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...
👍️0
Stockexpertpro Stockexpertpro 2 years ago
APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover
👍️0
IPO$ IPO$ 2 years ago
Closed out of puts at 99% profit on this one. Only three week hold.
👍️0
IPO$ IPO$ 2 years ago
Why is stock up so much???
👍️0
IPO$ IPO$ 2 years ago
Stock up big today.
👍️0
IPO$ IPO$ 2 years ago
FDA announcement soon.
👍️0
IPO$ IPO$ 2 years ago
Puts are very pricey and out of the money. Sell for cash to acct.
👍️0
IPO$ IPO$ 2 years ago
Why up today? As stock goes up, puts go up too. Strange.
👍️0
IPO$ IPO$ 2 years ago
Will we get FDA approval???
👍️0
IPO$ IPO$ 2 years ago
Heavy premium in the puts and calls.
👍️0
IPO$ IPO$ 2 years ago
2/8/23 regulatory decision due on Empavali.
👍️0
conix conix 3 years ago
Huge Market

👍️0
conix conix 3 years ago
Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: “It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: “In my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.
👍️0
PickleNick PickleNick 4 years ago
Going back to 60 this week
👍️0
wantprofits wantprofits 5 years ago
looks like insider dumping may be happening again.. damnit
👍️0
Pedro2004 Pedro2004 5 years ago
Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.
👍️0
ClayTrader ClayTrader 5 years ago
* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ComptonBrosInc ComptonBrosInc 5 years ago
First! Holding $40 2/21 call... waiting on trial results!
👍️0

Your Recent History

Delayed Upgrade Clock